alternative regulatory approaches, we selected those approaches that would maximize net benefits. Based on the analysis that follows, the Department believes that these proposed priorities are consistent with the principles in Executive Order 13563.

We also have determined that this regulatory action would not unduly interfere with State, local, and tribal governments in the exercise of their governmental functions.

In accordance with both Executive Orders, the Department has assessed the potential costs and benefits, both quantitative and qualitative, of this regulatory action. The potential costs are those resulting from statutory requirements and those we have determined as necessary for administering the Department’s programs and activities.

The benefits of the Disability and Rehabilitation Research Projects and Centers Program have been well established over the years. Projects similar to ones envisioned by the proposed priorities have been completed successfully, and the proposed priorities would generate new knowledge through research. The new DRRPs would generate, disseminate, and promote the use of new information that would improve outcomes for individuals with disabilities.

Intergovernmental Review: This program is not subject to Executive Order 12372.

Electronic Access to This Document: The official version of this document is available free at the site.

Time: 8:00 a.m. to 5:00 p.m.

Place: Embassy Suite at the Chevy Chase Pavilion, Washington, DC 20115.

Contact Person: Michelle Trout, Program Analyst, Office of Federal Advisory Committee Policy, National Institute of Child Health and Human Development, NIH, 6100 Executive Boulevard, Room 5B01–G, Bethesda, MD 20892–9304, (301) 435–6878, wetdeem@mail.nih.gov.

SUMMARY: The Food and Drug Administration (FDA) is extending the comment period by 30 days to April 29, 2015, for the notice entitled “Current Good Manufacturing Practice Requirements for Combination Products; Draft Guidance for Industry and Food and Drug Administration Staff; Extension of Comment Period.” In that document, FDA announced the availability of a draft guidance for industry and FDA staff and requested comments. The Agency is taking this action in response to a request for an extension to allow interested persons additional time to submit comments.

DATES: FDA is extending the comment period on the draft guidance. Submit either electronic or written comments by April 29, 2015.

ADDRESSES: Submit written requests for single copies of the draft guidance document entitled “Current Good Manufacturing Practice Requirements for Combination Products” to the Office of Combination Products, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 5129, Silver Spring, MD 20993–0002. Send one self-addressed adhesive label to assist that office in processing your request. See the SUPPLEMENTARY INFORMATION section for electronic access to the draft guidance document.

Submit electronic comments on the draft guidance to http://www.regulations.gov. Submit written comments to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. Identify comments with the docket number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT: John Barlow Weiner, Office of Combination Products, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 5129, Silver Spring,
DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Advisory Committee for Women’s Services (ACWS); Notice of Meeting

Pursuant to Public Law 92–463, notice is hereby given of a meeting of the Substance Abuse and Mental Health Services Administration’s (SAMHSA) Advisory Committee for Women’s Services (ACWS) on April 15, 2015.

The meeting will include discussions on lesbian, bisexual and transgender issues; high-risk/high-need girls and young women; supporting women in co-occurring disorders—core competencies, practices and strategies; SAMHSA's Pregnant and Post-Partum Women Grant Program; and a conversation with the SAMHSA Administrator.

The meeting is open to the public and will be held at SAMHSA, 1 Choke Cherry Road, Rockville, MD 20850, in the Rock Creek Conference Room.

Attendance by the public will be limited to space available. Interested persons may present data, information, or views, orally or in writing, on issues pending before the Committee. Written submissions should be forwarded to the contact person (below) on or before April 7, 2015. Oral presentations from the public will be scheduled at the conclusion of the meeting. Individuals interested in making oral presentations are encouraged to notify the contact person on or before April 7, 2015. Five minutes will be allotted for each presentation.

The meeting may be accessed via telephone. To attend on site, obtain the call-in number and access code, submit written or brief oral comments, or request special accommodations for persons with disabilities, please register on-line at: http://pac.samhsa.gov/Registration/meetingsRegistration.aspx, or communicate with SAMHSA’s Designated Federal Officer, Ms. Nadine Benton (see contact information below).

Substantive meeting information and a roster of Committee members may be obtained either by accessing the SAMHSAs’ Web site at: http://www.samhsa.gov/about-us/advisory-councils/advisory-committee-women%E2%80%99s-services-awcs, or by contacting Ms. Benton. Committee Name: Substance Abuse and Mental Health Services Administration Advisory Committee for Women’s Services (ACWS).

Date/Time/Type: Wednesday, April 15, 2015, from 9:00 a.m. to 5:15 p.m. EDT: Open.

Place: SAMHSA, 1 Choke Cherry Road, Rock Creek Conference Room, Rockville, Maryland 20850.

Contact: Nadine Benton, Designated Federal Official, SAMHSA’s Advisory Committee for Women’s Services, 1 Choke Cherry Road, Rockville, Maryland 20857 (mail), Telephone: (240) 276–0127, Fax: (240) 276–2252, Email: nadine.benton@samhsa.hhs.gov.

Summer King, Statistician, SAMHSA.

[FR Doc. 2015–05816 Filed 3–12–15; 8:45 am]

BILLING CODE 4162–20–P